{"log_id": 6390060466188033331, "direction": 0, "words_result_num": 26, "words_result": [{"probability": {"variance": 0.019454, "average": 0.942583, "min": 0.469395}, "location": {"width": 241, "top": 129, "height": 33, "left": 156}, "words": "风险比<1,则本品更具优势"}, {"probability": {"variance": 0, "average": 0.99889, "min": 0.998222}, "location": {"width": 51, "top": 177, "height": 25, "left": 144}, "words": "图3"}, {"probability": {"variance": 0.002078, "average": 0.975601, "min": 0.80656}, "location": {"width": 735, "top": 138, "height": 63, "left": 255}, "words": "接受本品或安慰剂联合泼尼松或泼尼松龙加LHRH类似物或既往睾丸切除术治"}, {"probability": {"variance": 0.006214, "average": 0.965724, "min": 0.594378}, "location": {"width": 736, "top": 172, "height": 63, "left": 255}, "words": "疗的患者的无影像学进展生存期 Kaplan Meier曲线(第二次0S期中分析时"}, {"probability": {"variance": 0.005958, "average": 0.956994, "min": 0.802852}, "location": {"width": 111, "top": 234, "height": 29, "left": 260}, "words": "研究者审查"}, {"probability": {"variance": 0.006532, "average": 0.87919, "min": 0.774333}, "location": {"width": 70, "top": 452, "height": 28, "left": 213}, "words": "生,6"}, {"probability": {"variance": 0, "average": 0.999808, "min": 0.999808}, "location": {"width": 26, "top": 479, "height": 23, "left": 215}, "words": "存"}, {"probability": {"variance": 0, "average": 0.999054, "min": 0.999054}, "location": {"width": 25, "top": 501, "height": 23, "left": 217}, "words": "期"}, {"probability": {"variance": 0.011871, "average": 0.875081, "min": 0.766127}, "location": {"width": 22, "top": 710, "height": 22, "left": 620}, "words": "15"}, {"probability": {"variance": 0.005126, "average": 0.927312, "min": 0.825892}, "location": {"width": 92, "top": 767, "height": 23, "left": 355}, "words": "85389"}, {"probability": {"variance": 0.047271, "average": 0.803001, "min": 0.398765}, "location": {"width": 218, "top": 751, "height": 27, "left": 627}, "words": "9515538"}, {"probability": {"variance": 0.012016, "average": 0.819794, "min": 0.70797}, "location": {"width": 95, "top": 788, "height": 25, "left": 352}, "words": "4024"}, {"probability": {"variance": 0.05536, "average": 0.654984, "min": 0.35355}, "location": {"width": 287, "top": 773, "height": 30, "left": 560}, "words": "31313"}, {"probability": {"variance": 0.012387, "average": 0.947133, "min": 0.494136}, "location": {"width": 834, "top": 869, "height": 66, "left": 208}, "words": "在观察到333例死亡事件后,进行了计划的总生存期(0S)期中分析KA)。基于所观察到"}, {"probability": {"variance": 0, "average": 0.990788, "min": 0.990788}, "location": {"width": 18, "top": 870, "height": 20, "left": 279}, "words": "品"}, {"probability": {"variance": 0.00689, "average": 0.975615, "min": 0.486889}, "location": {"width": 856, "top": 917, "height": 65, "left": 168}, "words": "的临床获益,对本研究进行揭盲,并对安慰剂组受试者提供本品药物治疗。与安慰剂组相比"}, {"probability": {"variance": 0.026923, "average": 0.887691, "min": 0.376347}, "location": {"width": 870, "top": 967, "height": 59, "left": 170}, "words": "本品组受试者的总生存期较长死亡风险降低25%(HR=0.752:959C11.06:0.9342P=0097),"}, {"probability": {"variance": 0.010289, "average": 0.962049, "min": 0.565181}, "location": {"width": 872, "top": 1012, "height": 62, "left": 172}, "words": "但OS结果尚不成熟,期中分析结果未达到预定停止试验的具有统计学意义的界值见表92"}, {"probability": {"variance": 0.009445, "average": 0.960939, "min": 0.598698}, "location": {"width": 351, "top": 1078, "height": 40, "left": 174}, "words": "故此次热后继续跟踪受试者生存情况"}, {"probability": {"variance": 0.013991, "average": 0.952346, "min": 0.48117}, "location": {"width": 892, "top": 1103, "height": 61, "left": 218}, "words": "在观察到741例死亡事件后,进行了计划的0S最终分析(中位随访时间为49个月本一"}, {"probability": {"variance": 0.002946, "average": 0.976349, "min": 0.675096}, "location": {"width": 943, "top": 1134, "height": 80, "left": 175}, "words": "品治疗组和安慰剂治疗组分别有65%546例中有354例)和72%542例中有387例受试"}, {"probability": {"variance": 0.029888, "average": 0.860715, "min": 0.37505}, "location": {"width": 935, "top": 1199, "height": 59, "left": 179}, "words": "者死亡。本品治疗组死亡风险降低19.4%(HR=0806=95%C1:0.97:0931,=0305"}, {"probability": {"variance": 0.010682, "average": 0.956414, "min": 0.470338}, "location": {"width": 874, "top": 1247, "height": 55, "left": 181}, "words": "获益具有统计学意义,中位OS延长4.4个月(本品组为34.7个月,安慰剂组为30.3个月:见"}, {"probability": {"variance": 0.010606, "average": 0.970762, "min": 0.41528}, "location": {"width": 876, "top": 1295, "height": 53, "left": 181}, "words": "表9和图4)尽管安慰剂组有4%的受试者后续接受了本品治疗,但本品组依然有显著的临床"}, {"probability": {"variance": 0.003195, "average": 0.965166, "min": 0.867332}, "location": {"width": 86, "top": 1363, "height": 27, "left": 185}, "words": "获益优势"}, {"probability": {"variance": 0.008732, "average": 0.957445, "min": 0.509459}, "location": {"width": 873, "top": 1420, "height": 50, "left": 185}, "words": "表9:研究302:接受本品或安慰剂联合泼尼松或泼尼松龙加LHB转类似物或既往睾丸切除术治"}], "language": 3}